Precision BioSciences (NASDAQ:DTIL) Receives Buy Rating from HC Wainwright

Precision BioSciences (NASDAQ:DTIL)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $60.00 price target on the stock.

A number of other equities research analysts also recently commented on DTIL. Weiss Ratings upgraded Precision BioSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 8th. JonesTrading reiterated a “buy” rating and set a $30.00 price objective on shares of Precision BioSciences in a report on Friday, April 17th. Finally, Oppenheimer began coverage on shares of Precision BioSciences in a report on Tuesday, June 9th. They set an “outperform” rating and a $20.00 price objective on the stock. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $32.25.

Precision BioSciences Stock Performance

Shares of DTIL opened at $6.99 on Monday. Precision BioSciences has a 52-week low of $3.53 and a 52-week high of $9.62. The company has a market cap of $180.36 million, a price-to-earnings ratio of -1.90 and a beta of 1.25. The company has a debt-to-equity ratio of 0.29, a quick ratio of 14.02 and a current ratio of 14.02. The stock has a fifty day moving average price of $7.35 and a two-hundred day moving average price of $6.23.

Precision BioSciences (NASDAQ:DTIL) last announced its earnings results on Tuesday, May 5th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.09). The company had revenue of $10.84 million for the quarter, compared to analyst estimates of $4.05 million. Precision BioSciences had a negative return on equity of 85.37% and a negative net margin of 96.73%. Analysts predict that Precision BioSciences will post -2.21 EPS for the current fiscal year.

Institutional Investors Weigh In On Precision BioSciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its holdings in shares of Precision BioSciences by 5.5% in the 2nd quarter. Geode Capital Management LLC now owns 77,712 shares of the company’s stock valued at $326,000 after acquiring an additional 4,025 shares in the last quarter. Miller Financial Services LLC grew its stake in Precision BioSciences by 50.0% in the fourth quarter. Miller Financial Services LLC now owns 15,000 shares of the company’s stock valued at $62,000 after purchasing an additional 5,000 shares in the last quarter. Lynx1 Capital Management LP grew its stake in Precision BioSciences by 0.6% in the third quarter. Lynx1 Capital Management LP now owns 1,042,596 shares of the company’s stock valued at $5,755,000 after purchasing an additional 6,545 shares in the last quarter. Quarry LP increased its position in shares of Precision BioSciences by 15.1% during the 4th quarter. Quarry LP now owns 68,311 shares of the company’s stock worth $284,000 after purchasing an additional 8,936 shares during the last quarter. Finally, HBK Sorce Advisory LLC acquired a new position in shares of Precision BioSciences during the 4th quarter worth approximately $38,000. 37.99% of the stock is owned by institutional investors.

Precision BioSciences Company Profile

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.